Detalles de la búsqueda
1.
Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study).
J Antimicrob Chemother
; 76(12): 3263-3271, 2021 11 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34459889
2.
Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study.
J Antimicrob Chemother
; 76(3): 738-742, 2021 02 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33200210
3.
Incidence and Severity of SARS-CoV-2 Infection in HIV-Infected Individuals During the First Year of the Pandemic.
J Acquir Immune Defic Syndr
; 89(5): 511-518, 2022 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34954717
4.
Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance.
Open Forum Infect Dis
; 9(11): ofac610, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36447613
5.
Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).
EBioMedicine
; 55: 102779, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32408111
6.
Corrigendum to "Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)".
EBioMedicine
; 89: 104486, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36806001
Resultados
1 -
6
de 6
1
Próxima >
>>